Loading
Led CAPTIVATE, which established fixed-duration ibrutinib plus venetoclax as a first-line option for CLL.
William Wierda was principal investigator of CAPTIVATE, the trial showing fixed-duration ibrutinib plus venetoclax produces high rates of undetectable MRD and durable remissions in untreated CLL and led to its approval in Europe, and led the MRD-guided cohort of that study. He chairs the NCCN CLL guidelines panel and helped develop the MD Anderson prognostic nomogram for CLL.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing, Chronic lymphocytic leukaemia and the tag cll.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing, Chronic lymphocytic leukaemia and the tags cll, guidelines.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing, Chronic lymphocytic leukaemia and the tags cll, fixed-duration.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing, Chronic lymphocytic leukaemia and the tag cll.
Shares BCL-2, Venetoclax, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag cll.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag cll.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing.
Shares Venetoclax, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors.